115 related articles for article (PubMed ID: 22366274)
1. Dyskinetic patients show rebound worsening of affect after an acute L-dopa challenge.
Evans AH; Farrell MJ; Gibson SJ; Helme RD; Lim SY
Parkinsonism Relat Disord; 2012 Jun; 18(5):514-9. PubMed ID: 22366274
[TBL] [Abstract][Full Text] [Related]
2. Acute dopamine boost has a negative effect on plasticity of the primary motor cortex in advanced Parkinson's disease.
Kishore A; Popa T; Velayudhan B; Joseph T; Balachandran A; Meunier S
Brain; 2012 Jul; 135(Pt 7):2074-88. PubMed ID: 22609619
[TBL] [Abstract][Full Text] [Related]
3. Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson's disease.
Warren Olanow C; Kieburtz K; Rascol O; Poewe W; Schapira AH; Emre M; Nissinen H; Leinonen M; Stocchi F;
Mov Disord; 2013 Jul; 28(8):1064-71. PubMed ID: 23630119
[TBL] [Abstract][Full Text] [Related]
4. Do dyskinesia and pain share common pathophysiological mechanisms in Parkinson's disease?
Lim SY; Farrell MJ; Gibson SJ; Helme RD; Lang AE; Evans AH
Mov Disord; 2008 Sep; 23(12):1689-95. PubMed ID: 18709675
[TBL] [Abstract][Full Text] [Related]
5. Risk factors in development of motor complications in Chinese patients with idiopathic Parkinson's disease.
Kum WF; Gao J; Durairajan SS; Man SC; Xie LX; Lu JH; Fong WL; Li M
J Clin Neurosci; 2009 Aug; 16(8):1034-7. PubMed ID: 19428256
[TBL] [Abstract][Full Text] [Related]
6. Beginning-of-dose and rebound worsening in MPTP-treated common marmosets treated with levodopa.
Kuoppamäki M; Al-Barghouthy G; Jackson M; Smith L; Zeng BY; Quinn N; Jenner P
Mov Disord; 2002 Nov; 17(6):1312-7. PubMed ID: 12465074
[TBL] [Abstract][Full Text] [Related]
7. [Effectiveness of slow release L-DOPA/benserazide in treatment of end-of-dose akinesia in Parkinson disease].
Eichhorn TE; Schrag A; Trenkwalder C; Selzer R; Kohnen R; Oertel WH; Poewe W
Nervenarzt; 1995 Dec; 66(12):933-41. PubMed ID: 8584079
[TBL] [Abstract][Full Text] [Related]
8. Mavoglurant (AFQ056) in combination with increased levodopa dosages in Parkinson's disease patients.
Kumar R; Hauser RA; Mostillo J; Dronamraju N; Graf A; Merschhemke M; Kenney C
Int J Neurosci; 2016; 126(1):20-4. PubMed ID: 24007304
[TBL] [Abstract][Full Text] [Related]
9. [Benefit of L-DOPA-without-DCI (decarboxylase inhibitor) therapy on wearing-off phenomenon in advanced stages of Parkinson's disease patients].
Hironishi M; Miwa H; Kondo T
No To Shinkei; 2002 Feb; 54(2):127-32. PubMed ID: 11889758
[TBL] [Abstract][Full Text] [Related]
10. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia.
Muñoz A; Li Q; Gardoni F; Marcello E; Qin C; Carlsson T; Kirik D; Di Luca M; Björklund A; Bezard E; Carta M
Brain; 2008 Dec; 131(Pt 12):3380-94. PubMed ID: 18952677
[TBL] [Abstract][Full Text] [Related]
11. Involvement of the subthalamic nucleus in impulse control disorders associated with Parkinson's disease.
Rodriguez-Oroz MC; López-Azcárate J; Garcia-Garcia D; Alegre M; Toledo J; Valencia M; Guridi J; Artieda J; Obeso JA
Brain; 2011 Jan; 134(Pt 1):36-49. PubMed ID: 21059746
[TBL] [Abstract][Full Text] [Related]
12. [Social and economic cost of L-Dopa-induced dyskinesias in patients with Parkinson's disease].
Maurel F; Lilliu H; Le Pen C
Rev Neurol (Paris); 2001 May; 157(5):507-14. PubMed ID: 11438770
[TBL] [Abstract][Full Text] [Related]
13. Levodopa in the early treatment of Parkinson's disease.
Murata M
Parkinsonism Relat Disord; 2009 Jan; 15 Suppl 1():S17-20. PubMed ID: 19131036
[TBL] [Abstract][Full Text] [Related]
14. Factors associated with motor fluctuations and dyskinesia in Parkinson Disease: potential role of a new melevodopa plus carbidopa formulation (Sirio).
Stocchi F; Marconi S
Clin Neuropharmacol; 2010 Jul; 33(4):198-203. PubMed ID: 20414107
[TBL] [Abstract][Full Text] [Related]
15. Helicobacter pylori infection and motor fluctuations in patients with Parkinson's disease.
Lee WY; Yoon WT; Shin HY; Jeon SH; Rhee PL
Mov Disord; 2008 Sep; 23(12):1696-700. PubMed ID: 18649391
[TBL] [Abstract][Full Text] [Related]
16. A simple rodent assay for the in vivo identification of agents with potential to reduce levodopa-induced dyskinesia in Parkinson's disease.
Johnston TH; Lee J; Gomez-Ramirez J; Fox SH; Brotchie JM
Exp Neurol; 2005 Feb; 191(2):243-50. PubMed ID: 15649479
[TBL] [Abstract][Full Text] [Related]
17. l-DOPA changes ventral striatum recruitment during motor sequence learning in Parkinson's disease.
Kwak Y; Müller ML; Bohnen NI; Dayalu P; Seidler RD
Behav Brain Res; 2012 Apr; 230(1):116-24. PubMed ID: 22343069
[TBL] [Abstract][Full Text] [Related]
18. Switching L-dopa Therapy from Pulsatile to Pulse Administration Reduces Motor Complications in Parkinson's Disease.
Mostile G; Nicoletti A; Dibilio V; Luca A; Raciti L; Sciacca G; Cicero CE; Vasta R; Donzuso G; Contrafatto D; Zappia M
Clin Neuropharmacol; 2017; 40(1):6-10. PubMed ID: 27879548
[TBL] [Abstract][Full Text] [Related]
19. [Tandospirone citrate, a selective 5-HT1A agonist, alleviates L-DOPA-induced dyskinesia in patients with Parkinson's disease].
Kannari K; Kurahashi K; Tomiyama M; Maeda T; Arai A; Baba M; Suda T; Matsunaga M
No To Shinkei; 2002 Feb; 54(2):133-7. PubMed ID: 11889759
[TBL] [Abstract][Full Text] [Related]
20. Levodopa induced motor complications in Thai Parkinson's disease patients.
Kulkantrakorn K; Tiamkao S; Pongchaiyakul C; Pulkes T
J Med Assoc Thai; 2006 May; 89(5):632-7. PubMed ID: 16756048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
